頁籤選單縮合
題 名 | PCSK9 Inhibitor的簡介=The Introduction of PCSK9 Inhibitor |
---|---|
作 者 | 吳俊男; 蔡敏鈴; | 書刊名 | 藥學雜誌 |
卷 期 | 32:2=127 2016.06[民105.06] |
頁 次 | 頁34-37 |
分類號 | 418.227 |
關鍵詞 | 低密度脂蛋白膽固醇; 動脈硬化性心血管疾病; PCSK9抑制劑; Proprotein convertase subtilisin/kexin type 9 inhibitors; Low-density lipoprotein cholesterol; Hypercholesterolemia; |
語 文 | 中文(Chinese) |
中文摘要 | 降低低密度脂蛋白膽固醇 (Low-density lipoprotein cholesterol, LDL-C) 已成為動脈硬 化性心血管疾病 (Cardiovascular disease, CVD) 在臨床上預防和治療的基石。在過去的幾 十年中,史他汀 (statin) 類藥物是用於降低 LDL-C 最有效的藥物。然而,仍然有許多患 者在治療有所限制,包括了因耐受性不良或其他原因無法使用 statin,如家族性高膽固 醇血症患者等。因此,臨床上需要更安全和強效的降低 LDL-C 藥物。在臨床試驗中, Proprotein convertase subtilisin/kexin type 9 (PCSK9) 抑制劑是新一類的藥物,臨床上已證 實可有效降低50-65%的 LDL-C 和良好的安全性及有效性。本文綜述 PCSK9的抑制機制 及臨床試驗結果,供大家參考。 |
英文摘要 | Low-density lipoprotein cholesterol (LDL-C) reduction with statin is the cornerstone of atherosclerotic cardiovascular disease (CVD) prevention over the past few decades. However, an additional LDL-C lowering agent is needed in clinic for patients with genetic hypercholesterolemia, statin intolerance, or high risk of CVD and diabetes. In clinical trials, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new class of lowering LDL-C drugs that was demonstrated with a 50-65% efficacy and a favorable safety profile. This review focused on the mechanism of LDL-C reduction using PCSK9 inhibitor, as well as the phase III clinical trials of PCSK9 inhibitors. |
本系統中英文摘要資訊取自各篇刊載內容。